Sector News

Micron Biomedical receives funds to produce needle-free vaccines

November 19, 2023
Life sciences

US-based Micron Biomedical has received $23.6m in funding from the Bill & Melinda Gates Foundation for the bulk manufacturing of needle-free vaccines.

The vaccine, which is virtually painless to administer, works by applying the microarray technology to the skin and then pressing a button for delivery.

This technology cuts down cold chain requirements and permits community health workers to inoculate children in minutes. It could boost treatment and vaccine access in low and middle-income countries.

Micron is also developing a needle-free measles-rubella (MR) vaccine leveraging its microarray technology.

The vaccine is intended for children from nine months old, subject to regulatory approvals and further clinical trials.

The funding will aid in developing a manufacturing plant, which will facilitate commercialising a first-ever MR vaccine based on microarray technology.

Micron Biomedical CEO Steven Damon stated: “We’re grateful to the Bill & Melinda Gates Foundation for the grant that allows us to build on our collaborative track record of bringing effective and life-saving vaccines to children and adults in communities with limited infrastructure.

“By supporting Micron’s efforts to develop a state-of-the-art, high-quality and large-scale production facility to manufacture our microarray technology, we have an opportunity to greatly improve on access and availability of measles/rubella vaccines, as well as other traditionally injectable global health vaccines, in underserved populations around the world.”

In May 2023, Micron reported positive data from its Phase I/II trial analysing the MR vaccine delivered via the company’s microarray technology.

The trial evaluated the immunogenicity, acceptability and safety of the injection-free vaccine in adults, toddlers and infants aged nine months and above.

Source: pharmaceutical-technology.com

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach